Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma

被引:0
|
作者
Thomas E. Hutson
Ram Ganapathi
Paul Elson
Tarek Mekhail
Thomas Olencki
G. Thomas Budd
Ronald M. Bukowski
机构
[1] Cleveland Clinic Foundation;,Experimental Therapeutics Program, Taussig Cancer Center
[2] Cleveland Clinic Foundation;,Clinical Pharmacology Laboratory, Taussig Cancer Center
[3] Cleveland Clinic Foundation,Department of Hematology and Medical Oncology, Taussig Cancer Center
来源
Investigational New Drugs | 2004年 / 22卷
关键词
vinorelbine; phase I clinical trial; microtubule poisons; multi-drug resistance (MDR);
D O I
暂无
中图分类号
学科分类号
摘要
The anti-epileptic diphenylhydantoin (DPH; Dilantin®) selectively enhances the in vitro cytotoxicity of vinca microtubule poisons in both parent sensitive and multi-drug resistant (MDR) human tumor cells. The in vivo clinical activity of this combination has not been fully evaluated. Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicities, and preliminary antitumor activity of the combination of intravenous (IV) bolus vinorelbine (VRL) and oral diphenylhydantoin (DPH) in patients (pts) with refractory solid tumors. Methods: Cohorts of 3–6 pts with refractory cancer were treated with escalating doses of weekly IV bolus VRL (I –20.0 mg/m2; II –22.5 mg/m2; III –25.0 mg/m2; IV –27.5 mg/m2; V –30.0 mg/m2; VI –32.5 mg/m2) combined with a fixed oral dose of DPH (400 mg/day) until MTD or progression. During each 35 day cycle, pts received DPH 400 mg/day administered orally on Days −6 to Day +22 and weekly IV bolus infusion of VRL on Days +1, +8, +15, and +22. The cohort treated at the MTD was expanded to further define toxicity. Results: A total of 25 evaluable pts. (9 men; 16 women) were treated with VRL and DPH at dose levels I (n = 5), II (n = 3), III (n = 2), IV (n = 3), V (n = 7) and VI (n = 5) in 5 week cycles over a 16 month period. Dose limiting toxicity occurred at dose level VI (VRL 32.5 mg/m2) and included grade 3 leukopenia (n = 2), grade 3 neutropenia (n = 1) and grade 4 neutropenia (n = 1) occurring within the first cycle of treatment. There were no responses, however 9 pts had stable disease of variable duration (8–56 weeks) and received a median of 2 cycles of treatment (range 2–14). Conclusion: Intravenous bolus administration of VRL and oral administration of a fixed dose of DPH was well tolerated according to the schedule reported here. Although there were no responses, several patients had prolonged disease stabilization. The recommended phase II dose of VRL when used in this combination is 30 mg/m2.
引用
收藏
页码:277 / 284
页数:7
相关论文
共 50 条
  • [41] Phase I Clinical Trial of Vinorelbine in Tumor-Bearing Cats
    Pierro, J. A.
    Mallett, C. L.
    Saba, C. F.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2013, 27 (04) : 943 - 948
  • [42] A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma
    Tiersten, AD
    Nelsen, C
    Talbot, S
    Vahdat, L
    Fine, R
    Troxel, A
    Brafman, L
    Shriberg, L
    Antman, K
    Petrylak, DP
    CANCER, 2003, 97 (03) : 537 - 544
  • [43] Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
    Renata Ferrarotto
    Luana G. Sousa
    Yun Qing
    Diana Kaya
    Bettzy Stephen
    Dipti Jain
    Diana Bell
    Shubham Pant
    Apostolia M. Tsimberidou
    Filip Janku
    George Blumenschein
    Bonnie S. Glisson
    Jordi Rodon Ahnert
    Sarina A. Piha-Paul
    J. Jack Lee
    Michael K. Wong
    Charles Lu
    Funda Meric-Bernstam
    Aung Naing
    Advances in Therapy, 2021, 38 : 4581 - 4591
  • [44] Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors
    Piatek, Caroline I.
    Raja, Grace L.
    Ji, Lingyun
    Gitlitz, Barbara Jennifer
    Dorff, Tanya B.
    Quinn, David I.
    Hu, James
    El-Khoueiry, Anthony B.
    Pham, Huyen Q.
    Roman, Lynda
    Garcia, Agustin A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) : 1227 - 1234
  • [45] Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
    Ferrarotto, Renata
    Sousa, Luana G.
    Qing, Yun
    Kaya, Diana
    Stephen, Bettzy
    Jain, Dipti
    Bell, Diana
    Pant, Shubham
    Tsimberidou, Apostolia M.
    Janku, Filip
    Blumenschein, George
    Glisson, Bonnie S.
    Ahnert, Jordi Rodon
    Piha-Paul, Sarina A.
    Lee, J. Jack
    Wong, Michael K.
    Lu, Charles
    Meric-Bernstam, Funda
    Naing, Aung
    ADVANCES IN THERAPY, 2021, 38 (08) : 4581 - 4591
  • [46] Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors
    Caroline I. Piatek
    Grace L. Raja
    Lingyun Ji
    Barbara Jennifer Gitlitz
    Tanya B. Dorff
    David I. Quinn
    James Hu
    Anthony B. El-Khoueiry
    Huyen Q. Pham
    Lynda Roman
    Agustin A. Garcia
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1227 - 1234
  • [47] A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Espinosa, E
    Zamora, P
    Millá, A
    Morales, S
    Molina, R
    Mira, M
    Barón, MG
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (12): : 1054 - 1059
  • [48] Phase I/II Trial of Vinorelbine and Sorafenib in Metastatic Breast Cancer
    Luu, Thehang
    Frankel, Paul
    Chung, Cathie
    Chow, Warren
    Mortimer, Joanne
    Hurria, Arti
    Somlo, George
    CLINICAL BREAST CANCER, 2014, 14 (02) : 94 - 100
  • [49] Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
    Kreis, W
    Budman, DR
    Fetten, J
    Gonzales, AL
    Barile, B
    Vinciguerra, V
    ANNALS OF ONCOLOGY, 1999, 10 (01) : 33 - 38
  • [50] Phase I trial of vinorelbine and sorafenib in metastatic breast cancer (MBC)
    Luu, T. H.
    Frankel, P. H.
    Chung, C. T.
    Mortimer, J. E.
    Hurria, A.
    McNamra, M.
    Koehler, S.
    Somlo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)